靶向抗癌治疗存在的问题及发展方向

由于靶向抗癌治疗中,存在癌细胞抗药性及转移等现象,有学者认为靶向抗癌治疗可能永远不会达到预期的治疗效果。靶向抗癌治疗已在白血病、肺癌等癌症的治疗中发挥了巨大的作用,在胰腺癌等多种癌症的临床研究中取得一定的进展,其面临的问题也是事物发展过程中的正常现象,不能因此否定靶向抗癌治疗的重要作用。在靶向抗癌治疗的发展过程中自觉地以哲学的方法论加以指导,有助于靶向抗癌治疗走出困境。可通过调整靶向抗癌治疗思维模式,突破传统靶标以及联合使用其他抗癌方法等途径,提高靶向抗癌治疗的整体临床受益。

Antiangiogenic agents combined with chemotherapy in non-small cell lung cancer

As a targeted therapy, antiangiogenic treatment has been increasingly studied for advanced non-small cell lung cancer(NSCLC) and has proven effective for the treatment of advanced NSCLC. Bevacizumab, a monoclonal antibody targeting angiogenesis, is the only antiangiogenic agent approved for use in combination with first-line chemotherapy for non-squamous NSCLC. Small-molecule inhibitors targeting the tyrosine kinase receptor have also shown promise when combined with standard chemotherapeutic agents in patients with advanced NSCLC. However, unlike bevacizumab, not all other antiangiogenic agents show significant benefits when combined with chemotherapy. As for the failures of most other combinations, the combination schedule may be an important reason that has so far been overlooked in clinical trials. This article reviews the combination of angiogenic agents with chemotherapy in the treatment of NSCLC.